Skip to main
  1. Stocks
  2. Hims & Hers Health
  3. Forecast
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 21%
Buy 7%
Hold 71%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is supported by a multi-engine growth model that pairs branded weight-loss momentum with expanding international scale and new specialty launches, helping offset near-term pressure from lower marketing spend and a sequential subscriber decline. Revenue of $890.4 million in 3Q26 grew 48.6% year over year, while average monthly revenue per subscriber rose to $105 and subscribers reached 2.788 million, signaling strong monetization even as the business reinvests for longer-term leadership. The company’s outlook is reinforced by its direct-to-consumer, self-pay model, deeper partnership access to Zepbound and Wegovy alternatives, and AI-led engagement improvements that management expects will lower cancellations, improve retention, and support operating leverage over time.

Bears say

Hims & Hers Health is facing a negative fundamental setup because revenue growth is increasingly being bought with weaker profitability: 3Q26 revenue of $890.4mm rose 48.6% Y/Y, yet gross margin fell to 57.2% and operating margin slipped to (0.2%) as branded GLP-1 sales and international mix diluted margins. Management also lowered FY26 adjusted EBITDA guidance to $257mm-$277mm and cut 4Q26 revenue and EBITDA below consensus, signaling that heavier marketing, pricing pressure in the UK and Germany, and subscriber deferrals are weighing on near-term earnings power. The company’s direct-to-consumer model remains vulnerable to intense competition, possible regulation around compounding and GLP-1s, and the strain of funding growth while carrying $1,368.0mm of debt against $712.2mm in cash and equivalents.

HIMS has been analyzed by 14 analysts, with a consensus rating of Hold. 21% of analysts recommend a Strong Buy, 7% recommend Buy, 71% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

HIMS Analyst Forecast & Price Prediction

Get the latest HIMS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HIMS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 14 analysts, HIMS has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


HIMS Analyst Forecast & Price Prediction

Get the latest HIMS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HIMS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HIMS stock data and trends